Study of new treatments for advanced squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests new drugs for people with advanced squamous non-small cell lung cancer that has gotten worse after standard treatments like immunotherapy and chemotherapy. The goal is to find better options for those who need them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IV squamous non-small cell lung cancer that has spread.
- Your cancer must have worsened after receiving immunotherapy (PD-1/PD-L1 treatment) and platinum-based chemotherapy.
- If you have HIV, it must be well controlled with medication.
- If you have hepatitis B or C, the virus must be undetectable with treatment.
- You cannot have certain heart, lung, eye, or autoimmune conditions, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatments for people with stage IV nonsquamous non-small cell lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It aims to find better options for those whose cancer has specific genetic features.
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
This study tests a new drug (7MW3711) against a standard chemotherapy (docetaxel) for people with advanced squamous non-small cell lung cancer that has progressed after prior chemo-immunotherapy. The goal is to see if the new drug is more effective or has fewer side effects.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This study tests a new combination of drugs (SYHX2011, carboplatin, and an immunotherapy called enlonstobart) as the first treatment for advanced squamous lung cancer that is PD-L1 positive. The goal is to see if this combination helps shrink tumors and slow cancer growth.
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
Hear when a new Lung Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.